Grail Inc. (NASDAQ:GRAL) Faces Challenges Amid Price Target Adjustment and Trial Results

Font: Financial Modeling Prep  • Feb 20, 2026

Grail Inc. (NASDAQ:GRAL) is a biotechnology company focused on early cancer detection. It is known for its multi-cancer screening test, Galleri, which aims to identify cancer at early stages. Grail operates in a competitive landscape with other biotech firms striving for breakthroughs in cancer diagnostics.

On February 20, 2026, Canaccord Genuity set a new price target of $80 for GRAL. At that time, the stock was trading at $101.53, indicating a potential downside of approximately -21.21% from the target. This adjustment reflects the market's reaction to recent developments surrounding Grail's performance.

Grail's stock has experienced a dramatic plunge of 50% following the release of its earnings report. The significant drop in stock price is attributed to the disappointing results from a U.K. trial of its multi-cancer screening test, Galleri. The trial revealed that the test did not achieve a "statistically significant reduction" in stage 3 and 4 cancer cases, impacting investor confidence.

Currently, GRAL is priced at $101.53, reflecting a decrease of 0.75, or -0.73% in percentage terms. Today, the stock has fluctuated between a low of $98.10 and a high of $102.52. Over the past year, GRAL has reached a high of $118.84 and a low of $20.44, indicating significant volatility in its stock price.

Grail's market capitalization stands at approximately $3.96 billion, with a trading volume of 1,545,372 shares on the NASDAQ exchange. The recent developments and price target adjustment by Canaccord Genuity highlight the challenges Grail faces in regaining investor confidence and stabilizing its stock performance.